Anzeige
Mehr »
Lynx Broker
Login
Samstag, 19.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12B8E ISIN: IE00BQPVQZ61 Ticker-Symbol: HPR 
Stuttgart
18.10.19
16:24 Uhr
24,800 Euro
-1,000
-3,88 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
HORIZON THERAPEUTICS PLC Chart 1 Jahr
5-Tage-Chart
HORIZON THERAPEUTICS PLC 5-Tage-Chart
RealtimeGeldBriefZeit
24,400
24,800
12:37
24,200
24,800
18.10.

Aktuelle News zur HORIZON THERAPEUTICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrHorizon Therapeutics initiates PROTECT clinical trial of KRYSTEXXA (pegloticase injection)1
HORIZON THERAPEUTICS Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!
DoFORTUNE and Great Place to Work Name Horizon Therapeutics plc to Best Small & Medium Workplaces List for Fourth Consecutive Year121Horizon Therapeutics plc (NASDAQ: HZNP) announced today that it has been selected to FORTUNE Magazine's 2019 "Best Medium Workplaces" list for the fourth consecutive year. Horizon ranked eighth out...
► Artikel lesen
DoHorizon Therapeutics launches PROTECT trial evaluating KRYSTEXXA in uncontrolled gout2
DoHorizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant108-- Trial to evaluate the effectiveness of KRYSTEXXA to sustain reduced serum uric acid levels for post-kidney transplant adults; a vulnerable population -- Horizon Therapeutics plc (Nasdaq: HZNP)...
► Artikel lesen
11.10.Horizon Therapeutics' Phase 3 trial finds 'significant benefit' of teprotumumab1
09.10.Horizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019165Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its third-quarter 2019 financial results will be released on Wednesday, Nov. 6, 2019. Following the announcement, Horizon's management...
► Artikel lesen
09.10.Horizon Therapeutics to move global HQ to 70 St Stephen's Green1
03.10.Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption186Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of the top 100 adoption-friendly workplaces in the country by the Dave Thomas Foundation for Adoption, ranking number...
► Artikel lesen
13.09.Horizon (HZNP) Up 36.7% YTD: Pipeline Development in Focus3
10.09.Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review1
09.09.Horizon Therapeutics: A Recession Resistant Pick With Upside Potential2
09.09.Horizon Therapeutics' Teprotumumab nabs accelerated review status for TED-
09.09.Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)162-- If Approved, Teprotumumab Would be the First FDA-Approved Medicine for this Vision-Threatening Disease -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug...
► Artikel lesen
30.08.Horizon Therapeutics Public Ltd Co - 8-K, Current Report2
28.08.Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer302Current Executive Vice President and Chief Business Officer, Robert F. Carey, will Retire Effective Oct. 1. - DUBLIN August 28, 2019 Horizon Therapeutics plc (Nasdaq: HZNP) today named Andy Pasternak...
► Artikel lesen
19.08.Horizon Therapeutics plc to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference178Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the company will participate in the following conference in September: Morgan Stanley 17th Annual Global Healthcare Conference...
► Artikel lesen
14.08.Horizon Therapeutics Has 'Headroom For Value Creation,' BMO Says In Upgrade2
14.08.Analysts Upgrade Drug Stocks HZNP and BMY24
14.08.Horizon Therapeutics plc Collaborates with Rare Disease Advocates to Elevate Resources and Shared Experiences Through Launch of RAREis Community Website226-- New website features resources, transitions support and personal stories of people living with rare diseases -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of RAREisCommunity.com...
► Artikel lesen
09.08.Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates3
Seite:  Weiter >>
77 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1